

Krzysztof Z. Łączkowski*, Konrad Misiura, Anna Biernasiuk, Anna Malm and Izabela Grela

Synthesis and antimicrobial activities of novel 6-(1,3-thiazol-4-yl)-1,3-benzoxazol-2(3H)-one derivatives

Abstract: Synthesis, characterization and investigation of antimicrobial activities of seven new 6-(1,3-thiazol-4-yl)-1,3-benzoxazol-2(3H)-ones are presented. Their structures were determined using ^1H NMR, ^{13}C NMR and elemental analyses. The compounds possess some biological activity against Gram-positive bacteria, especially against *Micrococcus luteus* belonging to opportunistic pathogens, with an MIC of 31.25 $\mu\text{g/mL}$.

Keywords: antimicrobial drugs; benzoxazolones; DFT calculation; Gram-positive bacteria; thiazoles; thiosemicarbazones.

***Corresponding author: Krzysztof Z. Łączkowski**, Faculty of Pharmacy, Department of Chemical Technology and Pharmaceuticals, Collegium Medicum, Nicolaus Copernicus University, Jurasza 2, 85-089 Bydgoszcz, Poland, e-mail: krzysztof.laczkowski@cm.umk.pl

Konrad Misiura: Faculty of Pharmacy, Department of Chemical Technology and Pharmaceuticals, Collegium Medicum, Nicolaus Copernicus University, Jurasza 2, 85-089 Bydgoszcz, Poland

Anna Biernasiuk and Anna Malm: Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Medical University, Chodźki 1, 20-093 Lublin, Poland

Izabela Grela: Faculty of Chemical Technology and Engineering, University of Technology and Life Sciences, Seminaryjna 3, 85-326 Bydgoszcz, Poland

Introduction

The observed increasing number of multidrug-resistant pathogens leads to the unprecedented interest in synthesis of new antimicrobial drugs [1]. Benzoxazolone derivatives are an important class of heterocyclic compounds widely studied in medicinal chemistry because they show a broad spectrum of activity against Gram-positive and Gram-negative bacteria and fungi [2–8], human immunodeficiency virus (HIV)-1 reverse transcriptase [9] and multidrug-resistant cancer cells [10, 11]. Various derivatives of benzoxazolone are commercially available, for example, benzolon **1** (myorelaxant), paraflex **2** (sedative analgesic) and vinizene **3** (topical antiseptic) [12]. The benzoyl-benzoxazolone **4** (10194 CERM) and its sulfur bioisoster **5**

(S-14080) have been studied in Phase II clinical trials as analgesic drugs (Figure 1) [12].

Another group of very important pharmacophores are thiazoles and their derivatives, which have been widely studied in medicinal chemistry because of their varied biological activities such as antibacterial [13–15], antifungal [16–18], anticancer [19] and antiproliferative activities [20]. This class of drugs prevents conversion of lanosterol into ergosterol, and accumulation of 14α -methyl sterols through inhibition of the fungal cytochrome P450 enzyme 14α -demethylase [21, 22].


Considering the above suggestions and continuing our previous investigation on the synthesis and properties of biologically active heterocycles [23–26], it was decided to prepare a new series of biologically active agents containing both benzoxazolone and thiazole pharmacophores. These compounds were evaluated for their *in vitro* antibacterial and antifungal activities against a panel of reference strains of 25 microorganisms.

Results and discussion

Chemistry

Initially, thiosemicarbazones were obtained by the reaction of appropriate ketones with thiosemicarbazide in absolute ethyl alcohol in the presence of catalytic amounts of acetic acid and under reflux. The desired benzoxazolone-thiazole conjugates **6–12** were synthesized via the Hantzsch condensation reaction of appropriate thiosemicarbazones with 6-(2-chloroacetyl)-benzo[d]oxazol-2(3H)-one (**13**) in absolute ethyl alcohol and under reflux with good yields (48–84%) and high chemical purity. The reaction pathway is summarized in Scheme 1.

The product **6** was obtained as a mixture of isomers *E/Z* in a 68:32 ratio; however, a careful separation using column chromatography gave pure, more stable (*E*)-isomer of compound **6**. Additionally, geometry optimization of **6** was carried out at the DFT B3LYP/6-311++G** level of theory using the Gaussian 09 code [27]. The resulting



Scheme 1 Synthesis of benzoxazolone-thiazole conjugates 6–12.





Figure 1 Commercial benzoxazolone derivatives 1–5.

electronic energy of the (*Z*)-isomer was 0.87 kcal/mol higher than that of the (*E*)-isomer. The fractional population X of isomers j (*E*, *Z*) (Figure 2) was calculated using the Boltzmann's distribution [28] as:

$$X_j = \frac{\exp(-\Delta_j E/kT)}{\exp(-\Delta_E E/kT) + \exp(-\Delta_Z E/kT)}$$



Relative ΔE [kcal/mol]	0.87	0
Theoretical <i>E/Z</i> ratio	81	19
Experimental <i>E/Z</i> ratio	68	32

Figure 2 The fractional population X of isomers j (*E*, *Z*).

with $\Delta_j E$ denoting the relative electronic energy of isomer j (calculated with regard to the energy of the lower-energy isomer *E*, i.e., the relative energy is 0 and 0.87 kcal/mol for isomers *E* and *Z*, respectively), k being

the Boltzmann constant, and T being the temperature ($T=298.15$ K) [29]. The *E*- and the *Z*-isomers were shown to constitute 81% and 19% of the population, respectively. This result is in a good qualitative agreement with the experimental one (68% and 32%, respectively). The structures and purity of all compounds (6–12) were confirmed by ^1H NMR, ^{13}C NMR, elemental analyses and by TLC on silica gel. The NMR spectral data were fully consistent with the assigned structures. ^1H NMR spectra of compounds show a singlet at δ 7.17–7.22 due to the thiazole-5H proton and a singlet at δ 10.80–11.95 indicating the presence of hydrazide NH proton, which confirms the conversion of substrates to the expected products. All compounds gave satisfactory elemental analysis. All reactions were repeated at least two times and are fully reproducible.

Microbiology

Potency was defined as follows: no bioactivity with MIC >1000 $\mu\text{g/mL}$, mild bioactivity with MIC in the

Table 1 Antibacterial activity data in MIC (MBC) ($\mu\text{g/mL}$) for benzoxazolone-thiazoles **6–12**.^a

Species	Benzoxazolone-thiazoles							
	6	7	8	9	10	11	12	CIP
<i>M. luteus</i> ATCC 10240	250 (>1000)	1000 (>1000)	500 (>1000)	–	1000 (>1000)	31.25 (250)	31.25 (250)	0.976

^aThe standard antibiotic, ciprofloxacin (CIP) was used as a positive control.

range of 501–1000 $\mu\text{g/mL}$, moderate bioactivity with MIC in the range of 126–500 $\mu\text{g/mL}$, good bioactivity with MIC in the range of 26–125 $\mu\text{g/mL}$, strong bioactivity with MIC in the range of 10–25 $\mu\text{g/mL}$ and very strong bioactivity with MIC <10 $\mu\text{g/mL}$. The antibacterial studies of compounds **6–8**, **10–12** against Gram-positive bacteria (staphylococci, streptococci, micrococci and *Bacillus* spp.) revealed some bioactivity against *Staphylococcus aureus* strains (i.e., *S. aureus* ATCC 25923, *S. aureus* ATCC 43300, *S. aureus* ATCC 6538, *S. aureus* NIL 1, *S. aureus* NIL 2) and *Staphylococcus epidermidis* ATCC 12228 with MIC values ranging from 250 to 1000 $\mu\text{g/mL}$. The MBC for the tested staphylococci was ≥ 1000 $\mu\text{g/mL}$. The compounds **6–8**, **10–12** show similar activity against *Bacillus subtilis* ATCC 6633 and *Bacillus cereus* ATCC 10876 with MIC between 500 and 1000 $\mu\text{g/mL}$ and MBC ≥ 1000 $\mu\text{g/mL}$. Among obtained compounds, **6–8** and **10** are also active against *Micrococcus luteus* ATCC 10240 with MIC=250–1000 $\mu\text{g/mL}$ and MBC ≥ 1000 $\mu\text{g/mL}$. In turn, **11** and **12** show good bioactivity with bacteriostatic effect against *M. luteus* ATCC 10240 with MIC=31.25 $\mu\text{g/mL}$, MBC=250 $\mu\text{g/mL}$ and MBC/MIC=8 (Table 1).

Moreover, minimum concentrations of **7**, **8**, **11**, **12**, which inhibit the growth of streptococci range from 500 to 1000 $\mu\text{g/mL}$ and MBC ≥ 1000 $\mu\text{g/mL}$.

Our results indicate that the tested compounds possess some activity against Gram-positive bacteria, especially against *M. luteus* belonging to the opportunistic pathogens. The tested compounds **6–12** have no influence on the growth of the reference strains of Gram-negative bacteria and of fungi belonging to *Candida* spp.

Conclusions

An efficient and economic method for the synthesis of benzoxazolone-thiazol conjugates was developed. The *in vitro* antimicrobial effects of the synthesized compounds on various pathogenic bacteria and fungi were evaluated. The tested compounds possess some biological activity against Gram-positive bacteria, especially against *M. luteus*, MIC 31.25 $\mu\text{g/mL}$ belonging to opportunistic pathogens. Interestingly, compound **9** containing an odd

number of carbon atoms in the ring is completely inactive. The bioactivity results provide good starting templates for further structural optimization of this type of derivative.

Experimental

Materials and methods

All experiments were carried out under air atmosphere. Reagents were generally the best quality commercial grade products and were used without further purification. ^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) spectra were recorded in DMSO- d_6 on a Bruker Ascend 400 multinuclear instrument. Melting points were determined in open glass capillaries and are uncorrected. Silica gel 60, E. Merck 230–400 mesh, was used for preparative column chromatography. Analytical TLC was performed using Macherey-Nagel Polygram Sil G/UV₂₅₄ 0.2 mm plates eluting with dichloromethane/methanol (9:1). 6-(2-Chloroacetyl)benzo[d]oxazol-2(3H)-one, thiosemicarbazide and appropriate ketones were commercial materials.

General procedure for the synthesis of compounds **6–12**

A mixture of the appropriate carbonyl compound (20 mmol), thiosemicarbazide (20 mL) and a catalytic amount of acetic acid (1 mL) in absolute ethyl alcohol (20 mL) was magnetically stirred for 24 h and heated under reflux. A precipitate of the desired thiosemicarbazone was filtered, crystallized from a suitable solvent and dried. This thiosemicarbazone (1.0 mmol) was added to a stirred solution of 6-(2-chloroacetyl)benzo[d]oxazol-2(3H)-one (**13**, 0.212 g, 1.0 mmol) in absolute ethyl alcohol (15 mL), and the mixture was stirred under reflux for 2 h. After cooling to room temperature, a colorless solid of **6–12** began to separate. The product was filtered off, washed with ethyl alcohol, then suspended in water and the mixture was neutralized with a NaHCO_3 solution. The crude product was subjected to silica gel column chromatography (230–400 mesh) using dichloromethane/methanol (9:1) as an eluent. Chromatography afforded a pure (*E*)-**6** isomer.

(E)-6-(2-(2-Ethylidenehydrazino)thiazol-4-yl)benzo[d]oxazol-2(3H)-one (6) Yield 0.16 g, (58%); R_f = 0.57; mp 250–253°C; ^1H NMR: δ 1.91 (d, 3H, CH_3 , J = 5 Hz), 7.10 (d, 1H, CH, J = 8 Hz), 7.19 (s, 1H, CH), 7.40 (q, 1H, CH, J = 5 Hz), 7.65 (dd, 1H, CH, J_1 = 2 Hz, J_2 = 8 Hz), 7.70 (m, 1H, CH), 11.75 (bs, 1H, NH, D_2O exchangeable), 12.19 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 18.4, 102.4, 106.9, 109.8, 121.7, 126.9, 130.5, 143.7, 145.2, 154.5, 164.8, 168.6. Anal. Calcd for $\text{C}_{12}\text{H}_{10}\text{N}_4\text{O}_2\text{S}$: C, 52.54; H, 3.67; N, 20.43. Found: C, 52.48; H, 3.55; N, 20.62.

6-(2-[2-(Propan-2-ylidene)hydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (7) Yield 0.24 g (84%); $R_f = 0.26$; mp 255–256°C; ^1H NMR: δ 1.95 (d, 3H, CH_3 , $J = 7$ Hz), 7.11 (d, 1H, CH, $J = 11$ Hz), 7.21 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.72 (m, 1H, CH), 10.90 (bs, 1H, NH, D_2O exchangeable), 11.77 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 18.1, 24.8, 102.6, 106.8, 109.9, 121.1, 127.3, 130.4, 143.8, 146.5, 153.1, 154.5, 169.7. Anal. Calcd for $\text{C}_{13}\text{H}_{12}\text{N}_4\text{O}_2\text{S}$: C, 54.15; H, 4.20; N, 19.43. Found: C, 54.23; H, 4.17; N, 19.48.

6-(2-[2-Cyclobutylidenehydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (8) Yield 0.20 g; (67%); $R_f = 0.86$; mp 258–259°C; ^1H NMR: δ 1.87–1.99 (m, 2H, CH_2), 2.93 (q, 4H, 2CH_2 , $J_1 = 7$ Hz, $J_2 = 14$ Hz), 7.10 (d, 1H, CH, $J = 11$ Hz), 7.18 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.72 (m, 1H, CH), 10.95 (bs, 1H, NH, D_2O exchangeable), 11.72 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 13.2, 33.4, 33.3, 102.2, 106.8, 109.8, 121.5, 128.6, 130.0, 143.7, 148.5, 154.5, 156.0, 169.2. Anal. Calcd for $\text{C}_{14}\text{H}_{12}\text{N}_4\text{O}_2\text{S}$: C, 55.99; H, 4.03; N, 18.65. Found: C, 56.06; H, 4.10; N, 18.71.

6-(2-[2-Cyclopentylidenehydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (9) Yield 0.19 g (60%); $R_f = 0.72$, mp 250°C (with decomp.); ^1H NMR: δ 1.70–1.75 (m, 2H, CH_2), 1.77–1.83 (m, 2H, CH_2), 2.37–2.43 (m, 4H, 2CH_2), 7.12 (d, 1H, CH, $J = 11$ Hz), 7.22 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.72 (m, 1H, CH), 10.95 (bs, 1H, NH, D_2O exchangeable), 11.82 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 24.5, 24.6, 29.2, 32.9, 102.5, 106.8, 109.9, 121.5, 127.2, 130.4, 143.8, 146.4, 154.5, 156.1, 169.4. Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_4\text{O}_2\text{S}$: C, 57.31; H, 4.49; N, 17.82. Found: C, 57.25; H, 4.40; N, 17.93.

6-(2-[2-Cyclohexylidenehydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (10) Yield 0.16 g (49%); $R_f = 0.74$; mp 248°C (with decomp.); ^1H NMR: δ 1.55–1.70 (m, 6H, 3CH_2), 2.26 (t, 2H, CH_2 , $J = 7$ Hz), 2.45 (t, 2H, CH_2 , $J = 6$ Hz), 7.11 (d, 1H, CH, $J = 11$ Hz), 7.20 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.68 (m, 1H, CH), 10.80 (bs, 1H, NH, D_2O exchangeable), 11.73 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 25.0, 25.6, 26.8, 27.8, 34.7, 102.7, 106.9, 109.9, 121.6, 126.3, 130.6, 143.8, 144.9, 154.4, 159.7, 169.8. Anal. Calcd for $\text{C}_{16}\text{H}_{16}\text{N}_4\text{O}_2\text{S}$: C, 58.52; H, 4.91; N, 17.06. Found: C, 58.60; H, 4.86; N, 17.15.

6-(2-[2-Cyclododecylidenehydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (11) Yield 0.30 g (73%); $R_f = 0.71$; mp 220–223°C; ^1H NMR: δ 1.15–1.45 (m, 14H, 7CH_2), 1.50–1.60 (m, 12H, CH_2), 1.65–1.75 (m, 2H, CH_2), 2.32 (t, 2H, CH_2 , $J = 6$ Hz), 2.40 (t, 2H, CH_2 , $J = 6$ Hz), 7.10 (d, 1H, CH, $J = 11$ Hz), 7.17 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.71 (m, 1H, CH), 11.95 (bs, 1H, NH, D_2O exchangeable), 11.72 (bs, 1H, NH, D_2O exchangeable); ^{13}C NMR: δ 21.79, 22.33, 22.46, 22.62, 23.04, 23.14, 23.58, 25.58 (two signals), 28.63, 30.58, 102.36, 106.65, 109.8, 121.4, 128.9, 129.9, 143.8, 148.8, 154.5, 170.3. Anal. Calcd for $\text{C}_{22}\text{H}_{28}\text{N}_4\text{O}_2\text{S}$: C, 64.05; H, 6.84; N, 13.58. Found: C, 64.11; H, 6.82; N, 13.65.

6-(2-[2-Adamantylidenehydrazino]thiazol-4-yl)benzo[d]oxazol-2(3H)-one (12) Yield 0.16 g; (42%); $R_f = 0.49$; mp 241–244°C; ^1H NMR: δ 1.70–1.80 (m, 6H, 3CH_2), 1.85–2.00 (m, 6H, 3CH_2), 2.54 (m, 2H, CH_2), 3.37 (m, 2H, CH_2), 7.10 (d, 1H, CH, $J = 11$ Hz), 7.19 (s, 1H, CH), 7.65 (dd, 1H, CH, $J_1 = 2$ Hz, $J_2 = 8$ Hz), 7.71 (m, 1H, CH), 11.95 (bs, 1H, NH, D_2O , exchangeable), 11.74 (bs, 1H, NH, D_2O exchangeable). ^{13}C NMR: δ 18.6, 27.2 (three signals), 31.8, 35.8, 37.3 (two signals), 56.1, 102.6, 106.9, 109.9, 121.6, 126.7, 130.5, 143.7, 145.5, 154.5, 165.6, 169.9. Anal. Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_4\text{O}_2\text{S}$: C, 63.14; H, 5.30; N, 14.73. Found: C, 63.19; H, 5.33; N, 14.81.

In vitro antimicrobial assay

Compounds **6–12** were screened *in vitro* for antibacterial and antifungal activities using the broth microdilution method according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) [30] and Clinical and Laboratory Standards Institute guidelines [31] against a panel of reference strains of 25 microorganisms, including Gram-positive bacteria (*Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Staphylococcus aureus* ATCC 43300, *Staphylococcus aureus* NIL1, *Staphylococcus aureus* NIL 2, *Staphylococcus epidermidis* ATCC 12228, *Streptococcus pyogenes* ATCC 19615, *Streptococcus pneumoniae* ATCC 49619, *Streptococcus mutans* ATCC 25175, *Bacillus subtilis* ATCC 6633, *Bacillus cereus* ATCC 10876, *Micrococcus luteus* ATCC 10240), Gram-negative bacteria (*Escherichia coli* ATCC 3521, *Escherichia coli* ATCC 25922, *Klebsiella pneumoniae* ATCC 13883, *Proteus mirabilis* ATCC 12453, *Bordetella bronchiseptica* ATCC 4617, *Salmonella typhimurium* ATCC 14028, *Enterobacter cloacae* NIL, *Pseudomonas aeruginosa* ATCC 9027, *Pseudomonas aeruginosa* ATCC 27853, *Pseudomonas aeruginosa* NIL) and fungi belonging to yeasts (*Candida albicans* ATCC 2091, *Candida albicans* ATCC 10231, *Candida parapsilosis* ATCC 22019). These microorganisms were obtained from the American Type Culture Collection (ATCC), routinely used for the evaluation of antimicrobials, and from the National Medicines Institute in Warsaw (NIL). All microbial cultures were first subcultured on nutrient agar or Sabouraud agar at 35°C for 18–24 h or 30°C for 24–48 h for bacteria and fungi, respectively.

The surface of Mueller-Hinton agar or Mueller-Hinton agar with sheep blood (for bacteria) and RPMI 1640 with MOPS (for fungi) were inoculated with the suspensions of bacterial or fungal species. Microbial suspensions were prepared in sterile saline (0.85% NaCl) with an optical density of McFarland standard scale 0.5 – approximately 1.5×10^8 CFU/mL for bacteria and 0.5 McFarland standard scale – approximately 5×10^5 CFU/mL for fungi. Samples containing examined compounds **6–12** were dissolved in DMSO and were dropped into the wells on the above-mentioned agar media. The agar plates were preincubated at room temperature for 1 h, and then they were incubated at 37°C for 24 h and 30°C for 48 h for bacteria and fungi, respectively. The well containing DMSO without any compound was used as the negative control and ciprofloxacin or fluconazole (Sigma) as positive controls.

Subsequently, minimal inhibitory concentration (MIC) of the compounds **6–12** was examined by the microdilution broth method, using their 2-fold dilutions in Mueller-Hinton broth or RPMI 1640 broth with MOPS prepared in 96-well polystyrene plates. Final concentrations of the compounds ranged from 1000 to 0.488 $\mu\text{g/mL}$. Microbial suspensions were prepared in sterile saline (0.85% NaCl) with an optical density of 0.5 McFarland standard. The bacterial or fungal suspension was added per each well containing broth and various concentrations of the examined compounds. After incubation, the MIC was assessed spectrophotometrically as the lowest concentration of the samples showing complete bacterial or fungal growth inhibition. Appropriate DMSO, growth and sterile controls were carried out. The medium with no tested substances was used as the control.

The MBC (minimal bactericidal concentration) or MFC (minimal fungicidal concentration) are defined as the lowest concentration of the compounds that is required to kill a particular bacterial or fungal species. MBC or MFC was determined by removing the culture using MIC determinations from each well

and spotting onto appropriate agar medium. After incubation, the lowest compound concentration with no visible growth observed was assessed as a bactericidal/fungicidal concentration. All experiments were repeated three times and representative data are presented [32].

The MBC/MIC or MFC/MIC ratios were calculated to determine the bactericidal/fungicidal ($\text{MBC/MIC} \leq 4$, $\text{MFC/MIC} \leq 4$) or bacteriostatic/fungistatic ($\text{MBC/MIC} > 4$, $\text{MFC/MIC} > 4$) effect of the tested compounds.

References

- [1] Heinemann, J. A.; Ankenbauer, R. G.; Amabile-Cuevas, C. F. Do antibiotics maintain antibiotic resistance? *Drug Discov. Today*. **2000**, *5*, 195–204.
- [2] Krawiecka, M.; Kuran, B.; Kossakowski, J.; Kierzkowska, M.; Młynarczyk, G.; Cieślak, M.; Kaźmierczak-Barańska, J.; Królewska, K.; Dobrowolski, M. A. Synthesis and biological activity of novel series of 1,3-benzoxazol-2(3H)-one derivatives. *Acta Pol. Pharm. Drug Res.* **2013**, *70*, 245–253.
- [3] Köksal, M.; Gökhan, N.; Erdogan, H.; Özalp, M.; Ekizoglu, M. Synthesis of 3-(4-substituted benzoylmethyl)-2-benzoxazolinones and screening antimicrobial activities. *Il Farmaco* **2002**, *57*, 535–538.
- [4] Erol, D. D.; Rosen, A.; Erdogan, H.; Yulug, N. Synthesis of some new Mannich bases derived from 6-acyl-3-(3,5-dimethylpiperidinomethyl)-2(3H)-benzoxazolones and their biological activities. *Arzneim.-Forsch. Drug Res.* **1989**, *39*, 851–853.
- [5] Erol, D. D.; Aytemir, M. D.; Yulug, N. Synthesis and antimicrobial activity of thiazolinomethyl-2(3H)-benzoxazolone derivatives (I). *Eur. J. Med. Chem.* **1995**, *30*, 521–524.
- [6] Kalcheva, V.; Mincheva, Z.; Andreeva, P. Synthesis and in vitro activity of new cephalosporin derivatives containing a benzoxazolone ring. *Arzneim.-Forsch. Drug Res.* **1990**, *40*, 1030–1034.
- [7] Soyer, Z.; Erac, B. Evaluation of antimicrobial activities of some 2(3H)-benzoxazolone derivatives. *FABAD J. Pharm. Sci.* **2007**, *32*, 167–171.
- [8] Erdogan, H.; Safak, C.; Ertan, M.; Yulug, N. Synthesis of some arylidenethiazolothiazoles and their antimicrobial activities. *J. Indian Chem. Soc.* **1989**, *66*, 45–47.
- [9] Deng, B. L.; Cullen, M. D.; Zhou, Z.; Hartman, T. L.; Buckheit, R. W., Jr.; Pannecouque, C.; De Clercq, E.; Fanwick, E. P.; Cushman, M. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. *Bioorg. Med. Chem.* **2006**, *14*, 2366–2374.
- [10] Murty, M. S. R.; Ram, K. R.; Venkateswara, R. R.; Yadav, J. S.; Venkateswara, R. J.; Cheriyan, V. T.; Anto, R. J. Synthesis and preliminary evaluation of 2-substituted-1,3-benzoxazole and 3-[(3-substituted)propyl]-1,3-benzoxazol-2(3H)-one derivatives as potent anticancer agents. *Med. Chem. Res.* **2011**, *20*, 576–586.
- [11] Ivanova, Y. B.; Momekov, G. T.; Petrov, O. G. New heterocyclic chalcones. Part 6. Synthesis and cytotoxic activities of 5- or 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolones. *Heterocycl. Commun.* **2013**, *19*, 23–28.
- [12] Poupaert, J.; Caratob, P.; Colacino, E. 2(3H)-Benzoxazolone and bioisosters as 'Privileged Scaffold' in the design of pharmacological probes. *Curr. Med. Chem.* **2005**, *12*, 877–885.
- [13] Parameshwarappa, G.; Lingamani, L.; Patil, S. B.; Goudgaon, N. M. Synthesis and anti-microbial activity of thiazole substituted coumarins. *Heterocycl. Commun.* **2009**, *15*, 343–348.
- [14] Chandak, N.; Kumar, P.; Sharma, Ch.; Aneja, K. R.; Sharma, P. K. Synthesis and biological evaluation of some novel thiazolylhydrazinomethylideneferrocenes as antimicrobial agents. *Lett. Drug Des. Discov.* **2012**, *9*, 63–68.
- [15] Kamal, A.; Adil, S. F.; Tamboli, J. R.; Siddardha, B.; Murthy, U. S. N. Synthesis of cyclodextrin derivatives of amino(thiazolyl) coumarins as potential antimicrobial agents. *Lett. Drug Des. Discov.* **2010**, *7*, 665–673.
- [16] Bharti, S. K.; Nath, G.; Tilak, R.; Singh, S. K. Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disubstituted thiazole ring. *Eur. J. Med. Chem.* **2010**, *45*, 651–660.
- [17] Chimenti, F.; Bizzarri, B.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; D'Ascenzio, M.; Lilli, D.; Rivanera, D. Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-*Candida* spp. agents. *Eur. J. Med. Chem.* **2011**, *46*, 378–382.
- [18] De Logu, A.; Saddi, M.; Cardia, M. C.; Borgna, R.; Sanna, C.; Saddi, B.; Maccioni, E. *In vitro* activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of *Candida* spp. and fluconazole-resistant *Candida albicans*. *J. Antimicrob. Chemother.* **2005**, *55*, 692–698.
- [19] Raghavendra, N. M.; Renuka, S.; Gupta, S. D.; Divya, P. Thiazole containing nitrogen mustards: synthesis, structural evaluation, cytotoxicity and DNA binding studies. *Lett. Drug Des. Discov.* **2011**, *8*, 838–842.
- [20] Patel, K.; Karthikeyan, C.; Solomon, V. R.; Hari Narayana Moorthy, N. S.; Lee, H.; Sahu, K.; Deora, G. S.; Trivedi, P. Synthesis of some coumarinyl chalcones and their antiproliferative activity against breast cancer cell lines. *Lett. Drug Des. Discov.* **2011**, *8*, 308–311.
- [21] Georgopadakou, N. H.; Walsh, T. J. Antifungal agents: chemotherapeutic targets and immunologic strategies. *Antimicrob. Agents Chemother.* **1996**, *40*, 279–291.
- [22] Sheehan, D. J.; Hitchcock, Ch. A.; Sibley, C. M. Current and emerging azole antifungal agents. *Clin. Microbiol. Rev.* **1999**, *12*, 40–79.

- [23] Łączkowski, K. Z.; Pakulski, M. M.; Krzemiński, M. P.; Jaisankar, P.; Zaidlewicz, M. Asymmetric synthesis of N-substituted N-hydroxyureas. *Tetrahedron Asymmetry* **2008**, *19*, 788–795.
- [24] Łączkowski, K. Z. Asymmetric synthesis of novel (1H-benzo[d]imidazol-2-ylthio)- and (di-n-butylamino-2-ylthio)acetamides. *Acta Pol. Pharm. Drug Res.* **2013**, *70*, 237–244.
- [25] Łączkowski, K. Z.; Misiura, K.; Biernasiuk, A.; Malm, A.; Siwek, A.; Plech, T. Synthesis, antimicrobial activities and molecular docking studies of novel 6-hydroxybenzofuran-3(2H)-one based 2,4-disubstituted 1,3-thiazoles. *Lett. Drug Des. Discov.* **2013**, *10*, 798–807.
- [26] Łączkowski, K. Z.; Czyżnikowska, Ż.; Zaleśny, R.; Baranowska-Łączkowska, A. The B–H–B bridging interaction in B-substituted oxazaborolidine–borane complexes: a theoretical study. *Struct. Chem.* **2013**, *24*, 1485–1492.
- [27] Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; et al. *Gaussian 09, Revision C.01*. Gaussian, Inc.: Wallingford, CT, 2009.
- [28] Marchesan, D.; Coriani, S.; Forzato, C.; Nitti, P.; Pitacco, G.; Ruud, K. Optical rotation calculation of a highly flexible molecule: the case of paraconic acid. *J. Phys. Chem. A* **2005**, *109*, 1449–1453.
- [29] Łączkowski, K. Z.; Baranowska, A. Conformational analysis and optical rotation of carene β-amino alcohols. A DFT study. *Eur. J. Org. Chem.* **2009**, *2009*, 4600–4605.
- [30] European Committee for Antimicrobial Susceptibility Testing (EUCAST). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. EUCAST discussion document E. Dis 5.1. *Clin. Microbiol. Infect.* **2003**, *9*, 1–7.
- [31] Clinical and Laboratory Standards Institute. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. M27-S4*. Clinical and Laboratory Standards Institute: Wayne, PA, 2012.
- [32] O'Donnell, F.; Smyth, T. J.; Ramachandran, V. N.; Smyth, W. F. A study of the antimicrobial activity of selected synthetic and naturally occurring quinolines. *Int. J. Antimicrob. Agents* **2010**, *35*, 30–38.